Bayer revealed in its second-quarter results update this morning that it has stopped the development of adrenomedullin pegol (PEG-ADM), which had reached phase 2 for the t
One of the less well-known symptoms of COVID-19 is inflammation and injury to blood vessels, and US biotech Aerpio Pharma thinks it has a drug that may help avert the life-threatening blood